Background Chronic plaque psoriasis is associated with overweight or obesity. Anti–tumour necrosis factor- α (anti-TNF- α ) treatments are now frequently used in psoriasis management. TNF- α is deeply involved in body weight homeostasis, which may be affected by TNF- α –targeted therapy. Objective To investigate whether anti-TNF- α treatments is associated with changes in body weight in patients with chronic plaque psoriasis. Methods We performed a retrospective controlled analysis comparing the variations in body weight and body mass index (BMI) in three closed cohorts of psoriatic patients during a 6-month treatment with etanercept ( N = 58), infliximab ( N = 40) or methotrexate ( N = 43). Results We observed a body weight increment of 1.5 ± 2.7 kg (mean ± SD; P = 0.0002) and 2.5 ± 3.3 kg ( P = 0.004) in patients treated with etanercept and infliximab, respectively. In contrast, a non-significant change (0.6 ± 1.4 kg; P = 0.4) was measured in patients treated with methotrexate. The BMI increased with 0.5 ± 0.5 ( P = 0.01) and 0.8 ± 1 ( P = 0.003) points in patients treated with etanercept and infliximab, respectively, whereas it did not change (< 0.2 ± 0.5; P = 0.06) in patients treated with methotrexate. About one fourth of patients experienced a 4- to 10-kg weight gain. Differences in body weight variations among patients treated with anti-TNF- α therapies and methotrexate were statistically significant ( P = 0.0005). We could not identify clinical parameters predicting this phenomenon. Conclusions Patients with psoriasis treated with long-term anti-TNF- α therapies may manifest a body weight gain. This effect should be taken into account in the global approach to patients with psoriasis.

Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study.

GISONDI, Paolo;COTENA, CLAUDIA;TESSARI, Gianpaolo;GIROLOMONI, Giampiero
2008

Abstract

Background Chronic plaque psoriasis is associated with overweight or obesity. Anti–tumour necrosis factor- α (anti-TNF- α ) treatments are now frequently used in psoriasis management. TNF- α is deeply involved in body weight homeostasis, which may be affected by TNF- α –targeted therapy. Objective To investigate whether anti-TNF- α treatments is associated with changes in body weight in patients with chronic plaque psoriasis. Methods We performed a retrospective controlled analysis comparing the variations in body weight and body mass index (BMI) in three closed cohorts of psoriatic patients during a 6-month treatment with etanercept ( N = 58), infliximab ( N = 40) or methotrexate ( N = 43). Results We observed a body weight increment of 1.5 ± 2.7 kg (mean ± SD; P = 0.0002) and 2.5 ± 3.3 kg ( P = 0.004) in patients treated with etanercept and infliximab, respectively. In contrast, a non-significant change (0.6 ± 1.4 kg; P = 0.4) was measured in patients treated with methotrexate. The BMI increased with 0.5 ± 0.5 ( P = 0.01) and 0.8 ± 1 ( P = 0.003) points in patients treated with etanercept and infliximab, respectively, whereas it did not change (< 0.2 ± 0.5; P = 0.06) in patients treated with methotrexate. About one fourth of patients experienced a 4- to 10-kg weight gain. Differences in body weight variations among patients treated with anti-TNF- α therapies and methotrexate were statistically significant ( P = 0.0005). We could not identify clinical parameters predicting this phenomenon. Conclusions Patients with psoriasis treated with long-term anti-TNF- α therapies may manifest a body weight gain. This effect should be taken into account in the global approach to patients with psoriasis.
psoriasis; anti TNF; weight gain
File in questo prodotto:
File Dimensione Formato  
2008_Gisondi-P._Girolomoni-G._J.-Eur.-Acad.-Dermatol.-Venereol._Anti-tumour-necrosis-factor--therapy-increases-body-weight-in-patients-with-chronic-plaque-psoriasis-A-retrospective-cohort-study_Jour.pdf

accesso aperto

Tipologia: Abstract
Licenza: Dominio pubblico
Dimensione 83.87 kB
Formato Adobe PDF
83.87 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11562/604363
Citazioni
  • ???jsp.display-item.citation.pmc??? 38
  • Scopus 154
  • ???jsp.display-item.citation.isi??? 142
social impact